Welcome to our dedicated page for Talis Biomedical news (Ticker: TLIS), a resource for investors and traders seeking the latest updates and insights on Talis Biomedical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Talis Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Talis Biomedical's position in the market.
Talis Biomedical Corporation (Nasdaq: TLIS) has appointed Brian Blaser as President, Chief Executive Officer, and Director, effective December 1, 2021. Blaser, a veteran in the in-vitro diagnostics sector with over 25 years of experience, previously led Abbott's global diagnostics organization. Kim Popovits, the interim CEO, will transition back to her role as Director. This leadership change comes after Talis received Emergency Use Authorization for its Talis One COVID-19 Test System, positioning the company for growth in the infectious disease testing market.
Talis Biomedical Corporation (NASDAQ: TLIS) announced that the FDA granted Emergency Use Authorization (EUA) for its Talis One™ COVID-19 Test System, enabling results in under 30 minutes. The system provides lab-quality testing in various healthcare settings and demonstrates 100% concordance with comparator test results. Talis One targets two genes to enhance sensitivity against COVID-19 variants, including Delta. Future developments may expand its testing capabilities to other infectious diseases. Further details will be provided during the Q3 earnings call on November 15, 2021.
Talis Biomedical Corporation (TLIS) announced it will release its third-quarter financial results on November 15, 2021, after market close. A conference call to discuss the results will follow at 1:30 PM PT (4:30 PM ET). Interested parties can join via phone or access a live webcast through the company's investor website. Talis is focused on developing innovative molecular diagnostic tests for infectious diseases, aiming to provide rapid, low-cost testing at the point of care with its Talis One device.
Talis Biomedical Corporation (Nasdaq: TLIS) announced the appointment of Kim Popovits as interim CEO following the resignation of Brian Coe as President, CEO, and Director. Popovits, former CEO of Genomic Health, will lead the search for a new CEO while enhancing the company's operational capabilities. The announcement emphasizes Talis's commitment to developing innovative molecular diagnostic testing solutions for infectious diseases at the point-of-care. The company is also focused on addressing the growing unmet need for accurate and rapid diagnostics.
Talis Biomedical Corporation (Nasdaq: TLIS) reported its Q2 2021 financial results, highlighting a revenue of $0.1 million, down from $0.8 million in Q2 2020. The significant net loss of $64.5 million was attributed to increased operating expenses of $64.5 million associated with manufacturing scale-up and test development. Talis successfully completed a clinical validation study for its Talis One™ COVID-19 assay and submitted an EUA application to the FDA on July 23, 2021. The company holds $313.5 million in cash and cash equivalents as of June 30, 2021, supporting its ongoing initiatives.
Talis Biomedical Corporation (TLIS) will release its second quarter financial results on August 10, 2021, after market close. A conference call will follow at 1:30 p.m. Pacific Time to discuss these results. The company is focused on developing innovative molecular diagnostic tests for infectious diseases, starting with COVID-19. Talis One, its primary product, aims to provide accurate and rapid testing at the point-of-care. Interested parties can access the call via telephone or through a live webcast on Talis' investor page.
Talis Biomedical Corporation (Nasdaq: TLIS) reported a significant increase in first-quarter 2021 revenue, reaching $7.0 million compared to $0.4 million in the prior year, driven by NIH RADx grant milestones. However, the company incurred a net loss of $60.5 million, up from $7.4 million the previous year, due to increased operating expenses of $67.5 million, largely from scaling manufacturing and commercial readiness for their Talis One platform. The firm completed its IPO, raising $232.5 million in net proceeds, positioning them for future growth.
Talis Biomedical Corporation (TLIS) announced that it will release its financial results for Q1 2021 after market close on May 11, 2021. A conference call will follow at 1:30 p.m. PT to discuss these results. The call can be accessed via telephone, with a live and archived webcast available on the company's investor website. Talis focuses on developing innovative molecular diagnostic tests for infectious diseases, aiming to provide accurate and rapid testing solutions, including its Talis One platform for COVID-19.
Talis Biomedical Corporation (TLIS) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. The company's management will present on May 12, 2021, at 8:00 a.m. PT / 11:00 a.m. ET. Interested investors can watch the live and archived webcast on Talis's website. Talis Biomedical is focused on developing innovative molecular diagnostic tests for infectious diseases, featuring its compact, cloud-enabled diagnostic platform, Talis One.
Talis Biomedical Corporation (Nasdaq: TLIS) announced the appointment of Jeryl Hilleman to its Board of Directors, effective March 18, 2021. Hilleman will also serve as Chair of the Audit Committee. CEO Brian Coe noted that her extensive experience in public company leadership within the life sciences sector will support Talis's growth strategy and transition towards the commercial launch of Talis One™, a diagnostic platform designed for rapid infectious disease detection. Hilleman holds over 20 years of financial leadership experience in the life sciences industry.